Loading organizations...
§ Private Profile · 153 Second Avenue Waltham, MA 02451 United States
Biotechnology company developing polymer pharmaceuticals for hemodialysis patients, focused on phosphorus control.
Key people at Geltex Pharmaceuticals, Inc..
Founded in 1992 by George Whitesides, Jim Tananbaum, Bob Carpenter, and Henry Blair, Waltham, Massachusetts-based Geltex Pharmaceuticals developed polymer-based therapies, focusing on non-absorbed polymers, polyamine analogues, and iron chelators. Under President and CEO Mark Skaletsky, the biotechnology firm successfully brought two drugs to market, including its lead product Renagel, which received FDA approval in 1998 to reduce serum phosphorus levels in hemodialysis patients. To commercialize this treatment, the company established a strategic joint venture with Genzyme in 1997 and raised just under eighty million dollars in total venture capital funding. The enterprise was fully acquired by its partner Genzyme in 2000 for an acquisition valuation of one billion four hundred million dollars. Following the transaction, the primary therapy was later rebranded as Renvela and eventually achieved over eight hundred fifty million dollars in annual sales.
Geltex Pharmaceuticals, Inc. was a biopharmaceutical company that developed polymer-based pharmaceuticals focused on non-absorbed polymers for gastrointestinal elimination of targeted substances, particularly to manage conditions in hemodialysis patients.[1][4] Its lead product, Renagel (sevelamer hydrochloride), addressed hyperphosphatemia by reducing serum phosphorus levels without systemic absorption, serving end-stage renal disease patients on dialysis.[1][6] The company solved unmet needs in phosphate binding for chronic kidney disease management, achieving clinical validation and market entry before its acquisition by Genzyme in December 2000, marking successful growth momentum from startup to exit.[1]
Founded in 1992 (with some sources noting 1991), Geltex Pharmaceuticals emerged in Waltham, Massachusetts, amid rising interest in polymer technologies for targeted drug delivery.[1][3] The founding team leveraged expertise in non-absorbed polymers, polyamine analogues, and iron chelators to pioneer therapies avoiding systemic side effects.[1][4] Early traction came via FDA interactions establishing Renagel as a non-absorbed drug, pivotal SEC filings for its Nasdaq IPO (ticker: GELX), and progression to commercialization, culminating in the 2000 Genzyme acquisition.[1][5][6]
Geltex rode the late-1990s biotech boom in targeted therapies for chronic diseases, particularly end-stage renal disease, amid growing dialysis populations and demand for safer phosphate management.[1] Timing aligned with FDA approvals for novel binders and investor enthusiasm for polymer-based innovations, influencing the shift toward non-systemic drugs in nephrology.[6] Market forces like rising chronic kidney disease prevalence favored its tech; post-acquisition, Renagel (rebranded Sevelamer) became a Genzyme blockbuster, shaping standards in renal care and inspiring polymer platforms in GI-targeted pharma.[1]
As an acquired entity integrated into Genzyme (now part of Sanofi), Geltex's legacy endures through Sevelamer's ongoing use in global renal therapy markets, with evolutions like extended-release formulations sustaining impact.[1] Future trends in kidney disease—such as precision nephrology and novel binders—build on its polymer foundation, potentially amplifying influence via next-gen non-absorbed therapies amid aging populations. Geltex exemplifies how focused polymer innovation can deliver enduring clinical and commercial value in biopharma.[1][6]
Key people at Geltex Pharmaceuticals, Inc..
